Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Wonder how the talk went at the conference:
Because according to the website it offered this :
Cutting-Edge Insights: Access the latest advancements in biomarker discovery, precision medicine, and clinical applications spanning cancer, immunology, neurodegenerative disorders, and cardiovascular biomarkers.
Innovative Immunotherapy: Dive into immune-oncology projects, exploring antibodies, cellular therapy, and immune checkpoint research. Contribute to interactive discussions, share your work, and stay updated on cutting-edge technologies and platforms.
Networking and Collaboration: Connect with industry leaders, researchers, and peers. Foster collaborations, engage in thought-provoking discussions, and explore partnership opportunities.
Professional Development: Enhance your skills with workshops on biomarker data analysis, machine learning, and artificial intelligence applications. Learn best practices and methodologies for biomarker and IO research.
Practical Applications: Discover how research translates into real-world applications. Explore exhibitor showcases, demonstrations, and case studies, gaining insights into the latest tools and technologies.
Personal and Industry Growth: Step out of your comfort zone, engage in interactive roundtables, and contribute to key discussions. Elevate your personal and professional growth within the dynamic fields of biomarker research and immunotherapy.
Https://vulpesinvest.com/wp-content/uploads/2023/09/Scancell-report-final-ver5.0-newformat-3.pdf
This report was 17 th of April 2023
The share price was 18.49 p
When “derisory share price “ mentioned
We now have an excellent management appointed and positive results in trial
The multiple quivers are hitting targets
Maybe 🤔 the chance to pick up shares less than 11 p have vanished and the direction is north bound at speed
Sorry the link doesn’t work
Markus 2
from other board had cut and pasted the info see below
I also add after Thursdays talk I imagine more new will be coming to the fore . A little media coverage would be helpful to start the kindling off and hopefully a healthy on fire share price . It’s been derisory far too long . The drip feed of RnS with a strong management team is everything that was advised in the Vulpes document. I will try to find and repost
It’s “trail blazing “ good luck to one and all
marcusl2: Apr 7 2024 3:00PM
CTMS01. Cancer Vaccines: Ready for Prime Time?
Clinical trial abstracts are under embargo and will be released at 3:00 PM ET on Friday, April 5.
Bermuda
poster at AACR in San Diego in April. Lindy Durrant is down to present in the 'Cancer Vaccines: Ready for Prime Time?' session and seems that we'll be getting the SCIB1 results.
'CT024 - A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma: Efficacy and safety results from the open-label Phase 2 SCOPE Trial'
Https://www.abstractsonline.com/pp8/#!/20272/session/663
Does this link work
Embargo is lifted on my birthday 5 th of April
From
21:38 marcusl2: GlyMab® and AvidiMab® platforms provide potential out licensing opportunities with active discussions ongoing with pharmaceutical and biotech companies (at least 4). We know one of these is correct.
Genmab
Biontech
BMS, Pfizer/Seagen
Eli Lilly, Roche/Genentech
Https://www.scancell.co.uk/Data/Sites/1/media/publications/posters/kaira-et-al-2022.pdf
Https://clinicaltrials.ucsf.edu/trial/NCT04993677
Seagen trial is it the one using Avidimab or am I just imagining that ?
It’s either way interesting trial
Please could someone let me know
Link to full event - immune-oncology-conference-London 7-8 th of March
https://events.marketsandmarkets.com/immuno-oncology-conference-london/#agenda
Just wondering why it’s not mentioned ceo of Scancell
A novel redirecting antibody targeting SCLC
Lindy Durrant, Professor, Cancer Immunotherapy, University of Nottingham, UK 14:45 - 15:15
A little reminder
EuroBiotech Report—Novartis, Immunocore-Scancell, Wren A round, Novo and BioNTech
This was from fierce pharma 2019
https://www.fiercebiotech.com/biotech/eurobiotech-report-novartis-immunocore-scancell-wren-a-round-novo-and-biontech
This was on linked in
We would like to say a BIG thank you to the organisations that supported this year's Melanoma Patient Conference! Our event would not be possible without our brilliant sponsors.
A special shout out to the extremely generous companies who donated products for this year's delegate goodie bags. 💙
University of Oxford
Bristol Myers Squibb
Scancell Ltd
Novartis
Pierre Fabre Group
Immunocore
Skcin - The Karen Clifford Skin Cancer Charity
Hello Sunday
Little Soap Company - BCorp™
Popcorn Kitchen Ltd
The Ginger People® / Ginger People Group
Ultra Violette Skincare
Nursem
La Roche-Posay Laboratoire Dermatologique
Pip Organic
Ego Pharmaceuticals
From Marcus 2 other board
University of Hong Kong (HKUMed), found that PD-1-enhanced DNA vaccination can induce sustained virus-specific CD8+ T cell immunity in an AIDS monkey model
https://www.globaltimes.cn/page/202403/1307969.shtml
9.25 prof Sarah Danson author of a recent poster
Giving updates on recent melanoma trials
https://melanomafocus.org/wp-content/uploads/2024/02/MPC24-Virtual-Brochure-2024-1.pdf
This why Genmab are interested in Glymab and why this is a very exciting area to be in . Found this article easily explaining the concept of something that’s been years in research
Cracking the sugar code: Why the ‘glycome’ is the next big thing in health and medicine
https://theconversation.com/cracking-the-sugar-code-why-the-glycome-is-the-next-big-thing-in-health-and-medicine-97750
Why do we care about glycans?
In the future, it is likely that analysis of an individual’s glycans will be used to predict our risk for developing diseases like rheumatoid arthritis, cancer or even food allergies. This is because glycome alterations can be specifically tied to particular disease states. Also, biological processes like aging are linked to inflammation in our glycome. It remains to be tested if reversing these changes can help prevent disease, or even slow aging – an intriguing possibility.
Along with DNA, proteins, and fats, glycans are one of the four major macromolecules essential for life. Of these four, glycans are the final arbiters of how our cells behave.
https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.3c01069
Tomorrow there will be anxious patients and interested clinicians seeing what is happening in drug trials
wish prof Sarah Danson. Good luck with her presentation.
it. This is ground, breaking scientific breakthroughs that Lindy Durant has been working on amost of her life, and I wish this “ beefed up team “ the best of luck, along with the patients who put their faith in going into Scancell trials
DYOR
A little of todays research showing what a little positive news can do to a share price
TIL therapy — a first of its kind — offers new hope for patients with metastatic melanoma
Iovance’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma
https://www.roswellpark.org/cancertalk/202402/til-therapy-first-its-kind-offers-new-hope-patients-metastatic-melanoma
Amtagvi also received Orphan Drug, Regenerative Medicine Advanced Therapy, Fast Track, and Priority Review designations.
https://www.fda.gov/news-events/press-announcements/fda-approves-first-cellular-therapy-treat-patients-unresectable-or-metastatic-melanoma
The share price of Iovance Biotherapeutics, Inc.
NasdaqGM: IOVA as of 27th of feb over a 12 months
Prev. Close 16.60
52 Wk. Low 3.21
52 Wk. High 17.60
*
Open 16.84
High 17.60
Low 16.15
Mkt Cap 4.87B
P/E (TTM) N/A
Div & Yield N/A & N/A
Cancer vaccines: 10 biotech companies that have changed the game
By Roohi Mariam Peter
10 mins
April 6, 2023
Updated
February 19,
https://www.labiotech.eu/best-biotech/cancer-vaccine-companies/
On this week , The Melanoma Patient Conference 2024Thursday 29th Feb- Friday 1st March 2024
https://melanomafocus.org
09:25am - 09:55am
Clinical Trials Update. Innovation and Progress (Professor Sarah Danson)
Prof Sarah Danson is involved in both Modi and Scancell melanoma trial ,
maybe a RNS this week before her presentation will give her more to talk about in 2024 ?
I have posted this before this is presentation is 2022 , after Poulam Patel prof Sarah Danson
https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2023.41.16_suppl.2566